Biotricity is revolutionizing cardiac care with its cutting-edge remote diagnostic and monitoring solutions that cater to a $35 billion total addressable market opportunity. By integrating advanced hardware and proprietary software, Biotricity has established a new paradigm in cardiac care. The Company’s robust technology platform and product ecosystem, featuring FDA-cleared smart cardiac monitors, coupled with a comprehensive cloud ecosystem, ensure seamless management of patient health across all stages of cardiac care. Utilized daily by cardiologists across 34 states and 500 centers, Biotricity has captured an 8% market share in cardiology, bolstered by a remarkable 99.2% retention rate and an LTV/CAC ratio of 9.

Biotricity reported record margins of 69.3% in FY24 and expects margins to improve to 80% in the near-term. The Company generated $12.1 million revenue in FY24 and is expected to reach a $20 million run rate in the near-term as Biotricity’s strategic partnerships with leading Integrated Delivery Networks (IDNs) and Group Purchasing Organizations (GPOs) are set to accelerate growth. Significantly, 93% of the Company’s trailing 12-month revenue is recurring, thanks to its technology-as-a-service model, paving a clear path to profitability with positive EBITDA anticipated before the end of calendar 2024. Biotricity’s leadership team has over 100 years of collective startup experience and a proven track record of successfully launching 70+ products in over 30 countries. With its strong technological foundation, clear path to profitability, strategic market positioning, and experienced leadership, Biotricity represents a compelling value proposition for investors seeking to capitalize on the rapidly evolving medtech space.